Phase II study of Pemetrexed and Cisplatin plus Bevacizumab with Maintenance Pemetrexed as First-Line Therapy for Nonsquamous Non-small-cell Lung Cancer (ALCT001)
Phase 2
- Conditions
- onsquamous Non-small-cell Lung Cancer
- Registration Number
- JPRN-UMIN000010804
- Lead Sponsor
- Kyorin Univercity Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1)active or symptomatic interstitial lung disease 2)clinically significant cardiovascular disease and DVT 3)medically uncontrolled hypertension and diabetes 4)clinically significant infectious disease 5)history of diverticulitis or clinically significant diverticular disease 6)history of gross hemoptysis (2.5ml) 7)primary tumor in close proximity to a major vessel 8)primary tumor with cavitation 9)melena 10)regular use of aspirin 11)proteinuria(Grade2) 12)history of thrombotic or hemorrhagic disorder 13)uncontrollable pleural effusion and ascites 14)symptomatic brain metastasis 15)active double cancer 16)pregnancy or lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point of this study was PFS, defined as the time from registration to the time of documented disease progression.
- Secondary Outcome Measures
Name Time Method Safety,Response rate,Disease control rate,OS,1-year survival rate,QO